2cureX presented progression in the IndiTreat® immuno-oncology assay development at the ESMO Immuno-Oncology Congress in Geneva 11-14 Dec. 2019.
December 13, 2019
Immuno-oncology (I-O) therapy for different types of cancer has contributed significantly to the cancer treatment landscape and is among the fastest growing areas within oncology (CAGR of 21,5%). However, clinical evidence is accumulating that I-O therapy often needs to be combined with other drug modalities to improve the long-term outcome for patients. The efficacy of such combinations in individual patients are best tested using a functional approach such as IndiTreat® measuring how well the drugs destroy cancer in biopsies from each patient.
In March 2017, 2cureX and the clinical partner, the University Medical Center Hamburg-Eppendorf (Universitätsklinikum Hamburg-Eppendorf, UKE), were awarded a grant of EUR 1,188,000 from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) to adapt the IndiTreat® to individualized immuno-oncology treatment.
A scientific abstract summarizing the progress of the project was selected for a poster presentation at this year’s ESMO Immuno-Oncology Congress in Geneva.
“With the generous support from the BMBF, we have been able to strengthen our collaborative efforts with several clinical and scientific partners at the UKE“ , says Tabea Sturmheit, Senior Research Scientist and she continues “Together we have made important progress to eventually offer a functional IndiTreat® test variant capable of predicting each patient´s response to a particular I-O drug and combinations of drugs”.
Henrik Harling, Chief Medical Officer, 2cureX says: “Immuno-oncological treatment starting in melanoma represented a gigantic progress in the treatment of a very serious disease and within the last couple of years, I-O drugs have been approved for a number of other cancers too. However, I-O is without effect in some patients for which the treatment is approved and in other cancers like colorectal only a minority of patients will benefit from current I-O drugs. The IndiTreat I-O test will become an important tool to identify those patients who will have a good result from a particular I-O treatment to the benefit for both patients and the health economy. We have high expectations for our test product and look forward to being able to offer it to the patients”.
For more information about 2cureX:
Ole Thastrup, CEO
Phone: +45 22 11 53 99
Svensk Kapitalmarknadsgranskning AB
Telephone: +46 70 755 95 51
This information is information that 2cureX AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on December 13th, 2019.
2cureX has developed the IndiTreat® (Individual Treatment Design) test. IndiTreat® establishes thousands of 3D micro-tumours that are functionally similar to the patient’s tumour and identifies the approved cancer treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient will be provided the selected treatment.
IndiTreat® is being clinically validated in eight clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.
IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.
IndiTreat® is presently being introduced into the European market through an Early Access Program.
The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol “2CUREX”).